Table 2.
Biodistribution of vancomycin in liver, kidney, lung, and spleen tissue after intravenous administration of a dose (5-mg/kg) of standard, conventional, and PEGylated liposomal vancomycin formulationsa
| Vancomycin formulation | Liver |
Kidney |
Lung |
Spleen |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AUC0–24 (μg · h/ml) | Cmax (μg/ml) | MRT (h) | AUC0–24 (μg · h/ml) | Cmax (μg/ml) | MRT (h) | AUC0–24 (μg · h/ml) | Cmax (μg/ml) | MRT (h) | AUC0–24 (μg · h/ml) | Cmax (μg/ml) | MRT (h) | |
| SV | 21.9 ± 5.3 | 1.1 ± 0.2 | 10.5 ± 1.6 | 58.6 ± 5.7 | 9.8 ± 1.2 | 9.9 ± 0.9 | 13.5 ± 2.1 | 3.0 ± 0.2 | 8.8 ± 1.9 | 99.4 ± 18.7 | 4.9 ± 1.0 | 13.8 ± 0.5 |
| CLV | 426.3 ± 44.3*** | 21.0 ± 1.1*** | 11.7 ± 0.9 | 51.7 ± 40.1 | 5.4 ± 0.7** | 11.1 ± 0.8 | 40.7 ± 13.5* | 5.5 ± 0.9** | 5.7 ± 1.3 | 1,563.1 ± 69.6*** | 68.8 ± 3.7*** | 12.6 ± 0.4* |
| PLV | 378.9 ± 36.4*** | 18.0 ± 3.8*** | 11.2 ± 1.3 | 44.6 ± 3.9* | 4.5 ± 0.9** | 10.7 ± 2.1 | 92.2 ± 10.1*** | 6.3 ± 1.5* | 11.1 ± 0.6 | 1,169.4 ± 86.3*** | 53.0 ± 1.2*** | 12.8 ± 0.5 |
a
SV, standard formulation; CLV, conventional formulation; PLV, PEGylated formulation.
Symbols *, **, and *** denote P values of <0.05, 0.01, and 0.001, respectively, versus parameters for the standard solution.